ESMO Deep Dive: Breast Cancer – Early Stage Triple-negative
This ESMO Webinar Series is available to all ESMO Members.
This ESMO Webinar Series is available to all ESMO Members.
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal…
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.
Cabozantinib shows promising activity in patients with MPPGs.
Application deadline: 31 May 2024 (12:00 CEST)
In a French noncomparative phase II trial, investigators established limited activity of FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus durvalumab or durvalumab/tremelimumab in the second-lin…
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Notice of Special Interest (NOSI): Administrative Supplement to Support the NCI Cancer…
HSC increase autophagy in response to mitochondrial stress and cytokine stimulation with IL-1β and TNF identified as key inducers.HSC and HPC require autop
Core services include processing of hematopoietic stem cells for autologous or allogeneic transplantation, generation of tumor vaccines using genetic or culture mediated modification of tumor…
James Cribbin and his wife, Alexandra, came to MD Anderson for its expertise in marginal zone lymphoma, a rare subtype of non-Hodgkin lymphoma. What they…
The combination of Lonsurf and talazoparib (Talzenna) selectively killed cancer cells with mutations in the TP53 gene, researchers found in a study in mice.